Blood Group Typing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Blood group typing includes the reagents, instruments, and software used by hospital blood banks, reference laboratories, and donor centers to identify ABO, Rh, and extended antigen profiles. Demand is driven by the steady global need for compatible blood in trauma care, surgery, oncology, obstetrics, and transplantation. The market is moving from labor-intensive serology toward automated and molecular platforms that improve throughput and reduce human error.

• •Estimated global value of around USD 3.2 billion in 2025.
• •Forecast compound annual growth rate of roughly 6.2% through the early 2030s.
• •PCR-based and genotyping techniques now command a leading share of method-based revenue.

Rising surgical volumes, an aging patient population, and more complex transfusion needs are lifting test volumes per procedure. Growth in solid-organ and hematopoietic stem cell transplants requires higher-resolution typing, while prenatal and pre-transfusion screening protocols are expanding in routine practice. Public and private investment in blood safety infrastructure, particularly in emerging economies, is opening new testing capacity.

• •Increasing demand for safe blood amid higher surgical and trauma caseloads worldwide.
• •Expanding organ and stem cell transplantation that requires extended antigen matching.
• •Greater investment in donor screening and blood bank automation in developing regions.

The market is commonly segmented by product (instruments, reagents and kits, and software/services), by test method (serology, PCR-based molecular typing, and microarray or NGS-based genotyping), and by end user (hospitals, blood banks, and diagnostic laboratories). North America leads on the back of mature transfusion medicine infrastructure and transplant volumes, while Asia-Pacific is the fastest-growing region as healthcare access broadens. Europe remains a sizeable, regulation-driven market tied to universal donor screening programs.

• •Reagents and consumables represent the largest recurring revenue stream within the product mix.
• •North America holds the leading regional share; Asia-Pacific is forecast as the fastest-growing region.
• •Hospital blood banks are the largest end-user segment, followed by independent reference laboratories.

What are the recent trends and outlook?

Adoption of molecular blood group genotyping is accelerating as laboratories seek to resolve weak D, rare antigens, and extended panels that are difficult to type by serology. Automation and middleware integration are reducing turnaround time and manual handling in high-volume donor centers. With a 6.2% growth trajectory, the market is expected to reach roughly USD 4.8-5.3 billion by the early 2030s, supported by broader prenatal screening, transplant expansion, and digital lab transformation.

• •Genotyping is gradually supplementing or replacing serology for extended antigen profiles.
• •Automation and lab IT integration are key purchase criteria for hospital blood banks.
• •Projected market size in the USD 4.8-5.3 billion range by the early 2030s on continued mid-single-digit growth.